Eigen Therapeutics
Eigen Therapeutics is dedicated to tackling tumor heterogeneity by utilizing a platform that designs combination therapies. They focus on improving targeted therapies such as antibody-drug conjugates and radioligand therapies by developing co-therapies that modulate the expression of cancer cell targets, aiming to reduce side effects and improve patient outcomes. Their platform leverages machine learning, automation, and a multidisciplinary team to scale co-therapy development, making targeted cancer treatments more effective and accessible.
Industries
Nr. of Employees
small (1-50)
Eigen Therapeutics
Redwood City, California, United States, North America
Products
Integrated co-therapy discovery platform
A platform that integrates high-throughput combinatorial screening, complex phenotypic in vitro models, automated robotics, lab operations software, and machine learning-driven heterogeneity analysis to identify and prioritize combination therapies.
Integrated co-therapy discovery platform
A platform that integrates high-throughput combinatorial screening, complex phenotypic in vitro models, automated robotics, lab operations software, and machine learning-driven heterogeneity analysis to identify and prioritize combination therapies.
Expertise Areas
- Co-therapy discovery for heterogeneous tumors
- High-throughput combinatorial screening
- Phenotypic assay development and in vitro tumor modeling
- Automated laboratory robotics and lab automation
Key Technologies
- High-throughput combinatorial screening
- Phenotypic screening assays
- Automated laboratory robotics
- Lab operations and workflow automation software